Compare Revvity Inc (RVTY) vs T Rowe Price Group Inc (TROW) Price & Performance

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

T. Rowe Price (TROW) trades at $105.47, up 1.35% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 10.46, net income margin of 29.26%, and consistent dividend growth spanning 40 years. Recent earnings beat expectations in Q1 and Q2 2026, while AUM reached $1.90 trillion in August 2026 despite net outflows.

The stock presents value characteristics with attractive valuation multiples and dividend yield near 5%, though technical weakness and analyst caution (63% hold rating) suggest near-term consolidation. Key catalysts include Q3 earnings due soon and the company's expansion into ETF offerings through F/m Investments acquisition, while risks include market-sensitive revenue and competitive pressures.